tbuckley/cabot-search huggingface dataset:
Abstract MS2-3: MS2-3 Clinical implications of DNA repair and genome instability research
Authors: A Tutt
Journal: Cancer Research (2017)

Abstract Breast cancer has now been subjected to extensive molecular characterisation. Although much attention has focused on transcriptional profiling, with consequent identification of a number of biological sub-types, it is clear that breast cancers show significant variability in their somatic genome. Breast cancers are diseases that are largely dominated by copy number aberrations (CNAs) rather than single nucleotide variants (SNVs). Although HER2 is the poster child CNA driven therapeutic target a number of other mutation and CNA candidates are being pursued. The mutational processes that drive the different forms of genomic instability in breast cancer are increasingly understood and have been described in the last year. These mutational and rearrangement signatures may reveal aberrations in the DNA damage response that themselves represent a vulnerability and a therapeutic target. I will discuss a range of strategies and clinical trials being employed to target DNA repair, genome instability and consequent replicative stress in breast cancer. I will also discuss the state of development of assays that categorise a range of forms of mutational signature and genome instability which may act in future as predictive biomarkers of therapy response or resistance to DNA damage response targeting therapies with utility in the clinic. Citation Format: Tutt A. MS2-3 Clinical implications of DNA repair and genome instability research [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr MS2-3.
Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
Authors: CF Singer, YY Tan, F Fitzal, GG Steger, D Egle, A Reiner, M Rudas, C Gruber, R Bartsch, M Fridrik, M Seifert, R Exner, M Balic, Z Bago-Horvath, M Filipits, M Gnant
Journal: Cancer Research (2017)

Abstract Purpose To evaluate whether pathological complete response to neoadjuvant trastuzumab is dependent on the level of HER2 amplification. Patients and Methods 114 women with HER2-overexpressing early breast cancer who had received neo-adjuvant trastuzumab in the prospective ABCSG-24 and ABCSG-32 trials, and for whom the HER2/CEP17 ratio was available, were included in this analysis. The ratio was correlated with tumor response as measured by the three most commonly used definitions of pathological complete response: ypT0 ypN0, ypT0/is ypN0, and ypT0/is. Results In trastuzumab-treated patients, ypT0 pN0 was achieved in 69.0% of patients with a HER2/CEP17 ratio of &amp;gt;6, but only in 30.4% of tumors with a ratio of ≤6 (p=0.001, Chi Square test). When pCR was defined by ypT0/is pN0 or by ypTis, 75.9% and 82.8% of tumors with a high ratio had a complete remission, while only 39.1%, and 38.3% with a low ratio achieved a pCR (p=0.002 and p&amp;lt;0.001, respectively). Logistic regression revealed that tumors with a higher HER2/CEP17 ratio had a significantly higher probability to achieve ypT0 ypN0 (OR: 5.08, 95% CI 1.86-13.90; p=0.002) than tumors with a low ratio, while none of the other clinicopathological parameters was predictive of pCR. The association between high HER2 amplification and pCR was almost exclusively confined to HR positive tumors (62.5% vs. 24.0%, 75.0% vs. 28.0%, and 87.5% vs. 28.0%, for ypT0 ypN0, ypT0/is ypN0, and ypT0/is; p=0.014, p=0.005, and p&amp;lt;0.001), and was largely absent in HR negative tumors. Conclusion A HER2/CEP17 ratio of &amp;gt;6 in the pre-therapeutic tumor biopsy is associated with a significantly higher pCR rate particularly in HER2 / HR co-positive tumors, and can be used to predict outcome before neoadjuvant trastuzumab is initiated. Citation Format: Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Gruber C, Bartsch R, Fridrik M, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M, For the Austrian Breast and Colorectal Cancer Study Group. Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-10.
Abstract IA07: Germline next-generation sequencing panels for detection of inherited colorectal cancer syndromes
Authors: Matthew B. Yurgelun
Journal: Cancer Research (2017)

Abstract Background: Germline genetic testing for hereditary cancer predisposition syndromes can prevent cancer and save lives by identifying individuals who will benefit from enhanced surveillance, prophylactic surgery, and other risk-reduction strategies. Classically, hereditary cancer risk assessment has involved identification of individuals with clinical histories that fulfill specific criteria for a given syndrome followed by germline testing for mutations in the associated gene(s). Recent advances in next-generation sequencing technologies now allow individuals to undergo germline evaluation of numerous genes in parallel and a growing array of multigene panels are clinically available for such diagnostic testing. Methods: This presentation will discuss updates in clinical genetic testing, specifically the growing availability of next-generation sequencing multigene panel testing for hereditary cancer risk assessment. Findings: Data regarding next-generation sequencing multigene panel testing will be presented and will be contrasted with traditional, syndrome-specific hereditary colorectal cancer risk assessment strategies. Particular areas of focus in this talk will include: the detection of unexpected/off-target germline mutations by multigene panels (e.g. BRCA1/2 mutations in patients with colorectal cancer); cost-effectiveness considerations; the significance of moderate-penetrance cancer susceptibility gene mutations; germline variants of uncertain significance; and ways in which multigene panel testing results are expanding knowledge (and uncertainty) about both well- and poorly-defined colorectal cancer predisposition syndromes. Conclusions: Next-generation sequencing multigene panels are rapidly growing in popularity and availability for assessing hereditary cancer risk, including the identification of germline mutations linked to inherited colorectal cancer risk. In order for patients considering such testing to receive optimal care, it is essential that both they and their providers have a clear understanding of the benefits and potential limitations of multigene panels, including the possibility of identifying unexpected and/or indeterminate germline results. Citation Format: Matthew B. Yurgelun. Germline next-generation sequencing panels for detection of inherited colorectal cancer syndromes. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr IA07.
A Multicentre Phase II Trial Testing Gemcitabine in the Treatment of Patients with Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma: SAKK 36/03.
Authors: Felicitas Hitz, Giovanni Martinelli, Emanuele Zucca, Walter Mingrone, Roger Von Moos, Mathew Simcock, Jenny Peterson, Sergio Cogliatti, Francesco Bertoni, Michele Ghielmini
Journal: Blood (2007)
Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival
Authors: Timur Mitin, C. Kristian Enestvedt, Ahmedin Jemal, Helmneh M. Sineshaw
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: There are no randomized data to guide clinicians treating patients with gallbladder cancer (GBC). Several retrospective studies reported the survival benefits of adjuvant radiotherapy (RT) and chemoradiation (CRT). In this paper, we examine whether these publications have impacted the utilization of adjuvant therapies and whether their survival benefits are evident in a contemporary cohort of patients. Methods: Using the National Cancer Data Base, we identified 5029 patients diagnosed with T1‐3N0‐1 GBC and treated with surgical resection from 2005 to 2013. We described trends in receipt of adjuvant treatments for three time periods (2005–2007, 2008–2010, 2011–2013) and calculated three-year overall survival (OS) probabilities for 2989 patients treated in 2005–2010. All statistical tests were two-sided. Results: The percentage of patients who received no adjuvant treatments was unchanged from 2005 to 2013. Adjuvant RT decreased from 4.2% to 1.7% (P < .001), adjuvant chemotherapy increased from 8.3% to 13.8% (P < .001), and adjuvant CRT remained stable at 15.9% (P = .98). Adjuvant treatments were associated with improved three-year OS, with adjusted hazard ratio of 0.47 (95% confidence interval [CI] = 0.39 to 0.58) for CRT, 0.77 (95% CI = 0.61 to 0.97) for chemotherapy, and 0.63 (95% CI = 0.44 to 0.92) for RT. Adjuvant CRT was associated with improved survival in all categories, except T1N0, and in patients with negative and positive margins. Conclusion: Over the past decade there was no increase in the utilization of adjuvant therapies in the United States for patients with resected GBC. Adjuvant therapy is associated with statistically significantly improved three-year OS. This analysis should form the basis for current clinical recommendations and support future prospective trials.
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice
Authors: Elisabeth Krones, Kathrin Eller, Marion J. Pollheimer, Silvia Racedo, Alexander H. Kirsch, Bianca Frauscher, Annika Wahlström, Marcus Ståhlman, Michael Trauner, Florian Grahammer, Tobias B. Huber, Karin Wagner, Alexander R. Rosenkranz, Hanns-Ulrich Marschall, Peter Fickert
Journal: Journal of Hepatology (2017)
Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS)
Authors: Caroline Houillier, Luc Taillandier, Thierry Lamy, Olivier Chinot, Cecile Molucon-Chabrot, Pierre Soubeyran, Remy Gressin, Sylvain Choquet, Gandhi Damaj, Antoine Thyss, Arnaud Jaccard, Vincent Delwail, Emmanuel Gyan, Laurence Sanhes, Jerome Cornillon, Reda Garidi, Alain Delmer, Alexia Savignoni, Ahmad AL Jijakli, Pierre Morel, Pascal Bourquard, Marie-Pierre Moles, Eric Deconinck, Pierre Morel, Thomas Gastinne, Jean-Marc Constans, Adriana Langer, Lucette Lacomblez, Daniel Delgadillo, Sylvain Dureau, Isabelle Turbiez, Anne-Sophie Plissonnier, Nathalie Cassoux, Valérie Touitou, Damien Ricard, Khê Hoang-Xuan, Carole Soussain
Journal: Blood (2016)
Human bronchial epithelium orchestrates dendritic cell activation in severe asthma
Authors: Delphine Gras, Asuncion Martinez-Anton, Arnaud Bourdin, Celine Garulli, Laure de Senneville, Isabelle Vachier, Joana Vitte, Pascal Chanez
Journal: European Respiratory Journal (2017)

The innate immune response is impaired in asthma, with increased epithelial release of C-X-C motif chemokine ligand (CXCL)8, interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP). We hypothesised that dendritic cells might modulate the hyperresponsive epithelium in severe asthma. For this purpose, we investigated epithelial–dendritic crosstalk in normal and diseased conditions, and because ultrafine particulate matter may affect asthmatic airways, we investigated its impact on this crosstalk. Air–liquid interface cultures of human bronchial epithelial cells (HBEC) of control subjects (cHBEC) or severe asthma patients (saHBEC) were co-cultured with monocyte-derived dendritic cells (moDC). Increased release of CXCL8, TSLP and IL-33 from saHBEC contrasted with cHBEC producing CXCL10 and CCL2. Regarding moDC activation, saHBEC co-cultures induced only upregulation of CD86 expression, while cHBEC yielded full moDC maturation with HLA-DR, CD80, CD86 and CD40 upregulation. Particulate matter stimulation of HBEC had no effect on cHBEC but stimulated CXCL8 and IL-33 release in saHBEC. Particulate matter impaired epithelium signalling (TSLP, IL-33 and CXCL8) in saHBEC co-cultures despite C-C chemokine ligand 2 induction. Crosstalk between HBEC and moDC can be established in vitro , driving a T1-type response with cHBEC and a T2-type response with saHBEC. Normal or asthmatic status of HBEC differentially shapes the epithelial–dendritic responses. We conclude that control moDC cannot rescue the hyperresponsive airway epithelium of severe asthmatics.
Arsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD+ Leukemic Cells through Depressed Production and Degradation of FLT3 Protein
Authors: Kozo Nagai, Lihong Hou, Li Li, Bao Nguyen, Courtney M Shirley, Hayley S Ma, Mark J. Levis, Amy S. Duffield, Donald Small
Journal: Blood (2016)
The prognostic factors for the recurred breast cancer patients with isolated, limited number of lung metastasis, and the implication of pulmonary metastasectomy
Authors: H. Yhim, S. Han, D. Oh, W. Han, S. Im, T. Kim, Y. Kim, D. Noh, S. Ha, Y. Bang
Journal: Journal of Clinical Oncology (2009)

1112 Background: In recurred breast cancer (BC) with isolated lung metastasis, the role of pulmonary metastasectomy (PM) is not established. Methods: We consecutively enrolled recurred BC patients (pts) with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital. Among 140 recurred pts with isolated lung metastasis, 45 had metastatic lesions less than 4. We analyzed the clinical outcomes of these 45 pts. Results: The median age was 49.0 (range 32–67) years. The median disease-free interval (DFI, Time from initial BC diagnosis to recur) was 26.1 (range 4.2–168.0) months, and the pts with DFI of less than 24 months were 20 (44%). The pts who had biologic subtypes (BS) of hormone receptor (HR)(+), HER-2(+), triple negative (TN) were 16 (36%), 14 (31%,) and 15 (33%), respectively. Fifteen (33%) had PM then followed by systemic treatment (PM group), and 30 received systemic treatment without PM (no PM group). There was no difference in terms of clinical factors such as DFI and BS between two groups. The median progression-free survival (PFS) and overall survival (OS) were 13.0 months (95% CI, 10.05–15.95) and 41.7 months (95% CI, 23.82–59.58), respectively. In univariate analysis, PFS was significantly longer in pts with PM (p &lt; 0.001), DFI of more than 24 months (p &lt; 0.001), and was marginally significant according to BS (p = 0.084). In multivariate analysis, DFI of less than 24 months (hazard ratio [H], 4.53; 95% CI, 1.72–11.90), no PM (H, 9.52; 95% CI, 3.34–27.18) and BS such as HER-2(+) (H, 3.00; 95% CI, 1.04–8.64) and TN (H, 3.92; 95% CI, 1.32–11.59) were independent prognostic factors for shorter PFS. In univariate analysis, OS was significantly longer in pts with PM (p = 0.011), DFI of more than 24 months (p &lt; 0.001), HR(+) BS (p = 0.009). In multivariate analysis, DFI of less than 24 months (H, 7.67; 95% CI, 2.00–29.43) and BS such as HER-2(+) (H, 3.70; 95% CI, 1.03–13.24) and TN (H, 3.27; 95% CI, 1.02–10.44) were independent prognostic factors for shorter OS. Conclusions: In recurred BC with isolated, limited number (less than 4) of lung metastasis, DFI and BS were prognostic factors for PFS and OS. PM also prolonged PFS, and, for OS, more follow-up is needed. Further prospective studies to define the role of PM are warranted. No significant financial relationships to disclose.
The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2
Authors: Ayalew Tefferi, Hagop M Kantarjian, Animesh D. Pardanani, Ruben A. Mesa, Robert C Newton, Peggy A Scherle, Timothy Burn, Srdan Verstovsek
Journal: Blood (2008)
Simple functional tests in COPD: stand up and be counted!
Authors: Matthew Maddocks, Claire M. Nolan, William D-C. Man
Journal: European Respiratory Journal (2017)

Chronic obstructive pulmonary disease (COPD) is widely recognised as a multisystem disorder [1]. Although forced expiratory volume in 1 s (FEV1) is a widely accepted marker used in the diagnosis and staging of COPD, it tells us very little about extra-pulmonary manifestations, such as skeletal muscle weakness and sarcopenia [2–4], and shares only a weak relationship with patient-centred outcomes of health-related quality of life and exercise capacity [5]. Pulmonary rehabilitation, the most effective non-pharmacological intervention in COPD, brings meaningful benefits to the patient, yet has little effect on FEV1. Hence, additional assessment tools are needed to provide a comprehensive picture of disease impact. Simple functional tests in COPD: sit to stand and gait speed can rapidly assess physical performance in COPD <http://ow.ly/jIRJ308ZsBg>
Preoperative PARPi and irradiation (POPI) for women with an incomplete response to neoadjuvant chemotherapy (NAC) for breast cancer: A phase I trial.
Authors: Richard C. Zellars, Julie R. Lange, Mehran Habibi, John H. Fetting, Vered Stearns
Journal: Journal of Clinical Oncology (2014)

TPS1142 Background: Fifty to seventy percent of breast cancer patients treated with NAC will have an incomplete response and ultimately worse outcomes than those with a pathologically complete response (pCR). Researchers hoping to increase the rate of pCR, added pre-operative radiation to NAC but had little success. One way to further increase the response to neoadjuvant radiation may be the concurrent use of an inhibitor of Poly(ADP-ribose)-polymerase (PARPi). Pre-clinical studies have shown that PARPi sensitizes cancer cells to radiation by inhibiting repair of radiation-induced ssDNA breaks. We hypothesize that POPI will increase the pCR rate in women who have residual disease after NAC. Before we can test this hypothesis, we must determine the max tolerable dose (MTD) of this combined therapy. Thus, we designed and opened a phase I trial of POPI in women with an incomplete response to NAC. Methods: Women with pathologically node positive disease before NAC and > 1.0 cm of residual disease after NAC are eligible. After obtaining consent the residual disease is biopsied. Patients with viable disease are enrolled in a standard 3+3 dose finding study of concurrent veliparib and pre-operative radiation. The starting dose of veliparib is 50 mg P.O. BID x 28 days and will increase by 50mg BID to a max of 200 mg BID. Radiation (235 cGy x 16) to the breast and regional nodes overlaps with the first 3 weeks of veliparib. Definitive surgery (lumpectomy/mastectomy) occurs 6 weeks after completion of radiation. The MTD is defined as the dose below the level at which >1dose limiting toxicity (DLT) is observed in 3-6 patients. An expansion cohort of 20 patients will be treated at the MTD for further evaluation. Status: This trial opened in 8/2013. Two patients have completed protocol therapy to date. Clinical trial information: NCT01618357.
Gene Expression Profiles (GEP) To Predict at Least Very Good Partial Response to Velcade, Doxil, and Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma.
Authors: Malathi Hari, James MacDonald, Judah Friedman, Tara Kendall, George Mulligan, Andrzej Jakubowiak
Journal: Blood (2007)
Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices
Authors: Alan P Skarbnik, Esprit Ma, Marie-Hélène Lafeuille, Jonathan Fortier, Tatyana Feldman, Mei Sheng Duh, Yvette Ng, Helgi van de Velde, Edward Dow, Liviu Niculescu, Vijayveer Bonthapally, Andre Goy
Journal: Blood (2014)
Erratum: Elevated donor cardiac troponin I: A marker of acute graft failure in infant heart recipients (Circulation (1994) 90 (2618-2621))
Authors: J. W. Grant, C. E. Canter, T. L. Spray, Y. Landt, J. E. Saffitz, J. H. Ladenson, A. S. Jaffe
Journal: Circulation (1995)
Erratum: Color flow imaging compared with quantitative Doppler assessment of severity of mitral regurgitation: Influence of eccentricity of jet and mechanism of regurgitation (J. Am. Coll. Cardiol. 1993; 21: 1211-1219)
Authors: M. Enriquez-Sarano, A. J. Tajik, K. R. Bailey, J. B. Seward
Journal: Journal of the American College of Cardiology (1993)
Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS
Authors: Victoria T Potter, Victoria J Tindell, Rachel Kesse-Adu, Janet Hayden, Patience Pasipanodya, Laura Reiff-Zall, Judith C. W. Marsh, Antonio Pagliuca, Aloysius Y Ho, ZiYi Lim, Ghulam J. Mufti
Journal: Blood (2010)
Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.
Authors: Sabine Kayser, Konstanze Doehner, Juergen Krauter, Heinz A. Horst, Marie von Lilienfeld-Toal, Ulrich Germing, Katharina Goetze, Michael Pfreundschuh, Walter Fiedler, Daniela Spaeth, Silja Groner, Brigitte Schlegelberger, Gudrun Goehring, Arnold Ganser, Hartmut Doehner, Richard F. Schlenk
Journal: Blood (2009)
Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Napoleon Santos, Randy A. Brown, Myron N Chang, Christopher R Cogle, John W. Hiemenz, W. Stratford May, Jan S Moreb, Maxim Norkin, John R. Wingard, Baldeep Wirk, Jack W Hsu
Journal: Blood (2011)
Prevalence of Anti-Human Factor VIII Binding IgG Antibodies in Sickle Cell Disease Patients before and after Hematopoietic Stem Cell Transplantation
Authors: Jay N Lozier, Eugene Park, Chutima Kumkhaek, Mary E Link, Wynona Coles, Tiffani Taylor, John F. Tisdale, Matthew Hsieh
Journal: Blood (2016)
Correction of Fanconi Anemia Mutation Using the Crispr/Cas9 System
Authors: Nozomu Kawashima, Yusuke Okuno, Yuko Sekiya, Xinan Wang, Atsushi Narita, Sayoko Doisaki, Michi Kamei, Nobuhiro Nishio, Hideki Muramatsu, Asahito Hama, Yoshiyuki Takahashi, Seiji Kojima
Journal: Blood (2015)
Abstract P5-14-04: Effects of dose-dense chemotherapy on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials
Authors: R Gray, R Bradley, J Braybrooke, C Davies, H Pan, R Peto, J Bliss, P Bruzzi, D Cameron, L Del Mastro, L Norton
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
Authors: Sébastien Le Burel, Stéphane Champiat, Emilie Routier, Sandrine Aspeslagh, Laurence Albiges, Tali-Anne Szwebel, Jean-Marie Michot, Pascale Chretien, Xavier Mariette, Anne-Laure Voisin, Olivier Lambotte
Journal: Annals of the Rheumatic Diseases (2017)

Although treatment with immune checkpoint inhibitors (ICIs) is associated with better survival in many cancer settings, these therapeutics can induce immune-related adverse events (IrAEs).1 ,2 REISAMICi is a French, prospective, multicentre, academic registry sponsored by the Gustave Roussy Institute cancer centre. The objective is to better detect, document and manage IrAEs.

Connective tissue diseases (CTD) have not previously been reported in patients treated with anti-PD1/PDL-1 agents. The REISAMIC registry was screened for reports of CTD.

Of the 447 patients supervised in the REISAMIC registry, three have developed CTD: two cases of Sjogren's syndrome and one case of cryoglobulinemic vasculitis as a complication of suspected Sjogren's syndrome (table 1). A case of ANA+ myositis registered in REISAMIC by another investigating centre …
Disease Characteristics, Treatment Patterns, and Patient Outcomes of Lymphoplasmacytic Lymphoma or Waldenstroms Macroglobulinemia: A Single Institution Retrospective Review
Authors: Shams B Bufalino, Malini M Patel, Kimberly R Kruczek, Farah E Nasraty, Vamsi Parini, Cara Joyce, Scott E Smith
Journal: Blood (2016)